ArticleObesity surgery2025
Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG).
methodsWe retrospectively analyzed 246 patients who underwent primary LSG in our institution and were followed up for at least 12 months. We collected body weights preoperatively and at three, six, 12, and 24 months postoperatively, along with body composition and laboratory results preoperatively and at 12 months. Data on obesity management medications were collected. The OMM adjuvant therapy protocol has been applied at our institution since 2021. The patients were classified into two contemporary cohorts by surgery year: 2019-2020 standard care + dietitian (SCD) and 2021-2024 standard care + dietitian + OMM protocol (OPG).
resultsOverall, 97 patients were in SCD and 149 in OPG. Patients had similar age, body mass index (BMI), and waist-to-hip ratio among the groups. The OPG group demonstrated significantly higher total body weight loss (TBWL) and excess body weight loss (EBWL) at three, six, and 12 months. In multivariable analyses, OPG had a trend toward higher odds of achieving TBWL ≥ 25% at 12 months (adjusted OR 2.413, 95% CI 0.939-6.204, p = 0.067) after LSG. By 24 months, between-group differences were not significant in complete-case analyses.
conclusionProtocolized use of OMM within the first year after LSG may enhance weight loss outcomes and offer a trend toward optimal clinical response, highlighting its potential in metabolic-bariatric care.
Indexed as
Identifiers
40931277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.